Ro52 Antigen - 0.2mg

Ro52 Antigen - 0.2mg

Regular price
$728.78
Regular price
Sale price
$728.78
Unit price
per 
Availability
Sold out

Ro52 antigen

Uniprot ID:  P19474
mRNA RefSeq:  NM_003141
Protein RefSeq:  NP_003132
Size: 0.2mg
Source: Recombinant
Catalogue Number: ATR05-02

Product Information

Autoantibodies to the Ro (SSA) antigen are one of the most frequent serological autoimmune markers in rheumatic diseases. Anti-Ro-positive sera may contain two different types of autoantibody; those directed to a 60 kDa and those directed to a 52 kDa polypeptide component (referred to as Ro60 and Ro52 respectively). While the vast majority of Ro(SSA) positive sera react with both of these components, anti-Ro60 antibody has been reported to occur without anti-Ro52 antibody only in SLE sera whereas anti-Ro52 antibody has been reported to occur in the absence of anti-Ro60 antibody in idiopathic inflammatory myopathy, dermatomyositis and scleroderma. 

Antibodies to Ro52 have been observed to occur not only monospecifically or with Ro(SSA)/La(SSB), but also concurrently with antibodies to Jo-1 and to other aminoacyl transferases, with anti-SRP, anti-PMScl, anti-CENP-B, anti-RNP and antihistones. The differing serological and clinical associations of anti-Ro52 and anti-Ro60 suggest that anti-Ro52 should be considered as an additional connective tissue disease serum marker, independent of anti-Ro60(SSA).
 
Ro52 is a member of the tripartite motif (TRIM) family of proteins. The TRIM motif includes three zinc-binding domains, a RING finger, a B-box type 1 and a B-box type 2, and a centre coiled-coil region (leucine zipper). TRIM proteins are believed to identify specific cell compartments through a process of homo-multimerisation. Other functional studies have suggested a role for a putative leucine zipper domain of Ro52 in protein dimer formation and inhibition of transcription activity, and involvement of Ro52 in the ubiquitin pathway.

Although autoantibodies are known to bind to multiple epitopes on the Ro52 protein, the leucine zipper domain and an area on the N-terminal side of it have been shown to constitute a prominent linear epitope. 
 

PDF-logo-dl Ro52 datasheet

Clinical Indications

Sjögren's syndrome
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Neonatal Lupus Syndrome
Dermatomyositis
Scleroderma

MSDS

PDF-logo-dl  Material Safety Data Sheet

References

Tan, E.M. (1989) Adv. Immunol. 44, 93

McCauliffe, D.P. & Sontheimer, R.D. (1993) J. Invest. Dermatol. 100,73

Chan, E.K.L. & Buyon, J.P. (1994) Man. Biol. Markers Dis. (Kluwer Acad. Publ.) B1/1-18

Ben-Chetrit, E. et al. (1990) Arthritis Rheum. 33, 349

Slobbe, R.L. et al. (1991) Clin. Exp. Immunol. 86, 99

Rutjes, S.A. et al. (1997) Clin. Exp. Immunol. 109, 32

Frank, M.B. et al. (1999) J. Autoimmun. 12, 137

Peene, I. et al. (2002) Ann. Rheum. Dis. 61, 1090

Peene, I. et al. (2002) Ann. Rheum. Dis. 61, 929

Reymond, A. et al. (2001) EMBO J. 20, 2140

Rhodes, D.A. et al. (2002) Immunol. 106, 246

Wang, D. et al. (2001) Biochim. Biophys. Acta 1568, 155

Di Donato, F. et al. (2001) Int. J. Biochem. Cell Biol. 33, 924

Fukuda-Kamitani, T. & Kamitani, T. (2002) Biochem, Biophys. Res.Comm. 292, 774

Bozic, B. et al. (1993) Clin. Exp. Immunol. 94, 227

McCauliffe, D.P. et al. (1994) J. Rheumatol. 21, 1073

Ricchiuti, V. Et al. (1994) Clin. Exp. Immunol. 95, 397

Frank, M.B. et al. (1994) Clin. Exp. Immunol.95, 390

St Clair, E.W. et al. (1994) Arthritis Rheum. 37, 1373

Blange, I. et al. (1994) J. Autoimmunity 7, 263

Peek, R. et al. (1994) J. Immunol. 153, 4321

Itoh, Y. et al. (1992) Autoimmunity 14, 89

Kurien, B.T. et al. (2001) Scan. J. Immunol. 53, 268

Ben-Chetrit, E. et al. (1988) J. Exp. Med. 167, 1560

McCauliffe, D.P. at al. (1997) J. Rheumatol. 24, 860

Pourmand, N. et al. (2000) Scan. J. Rheumatol. 29, 116